Sveriges Riksbank
| Bid date, 2021-02-09 | |
| Auction date | 2021-02-09 |
| Settlement date | 2021-02-10 |
| Maturity Date | 2021-02-17 |
| Nominal amount | 380 billion SEK |
| Interest rate, % | 0.00 |
| Bid times | 09.30-10.00 (CET/CEST) on the Bid date |
| Confirmation of bids to e-mail | rbcert@riksbank.se |
| The lowest accepted bid volume | 1 million SEK |
| The highest accepted bid volume | 380 billion SEK |
| Allocation Time | 10.15 (CET/CEST) on the Bid date |
| Projected minimum liquidity surplus during the term | 924 billion SEK |
| Expected excess liquidity at full allotment | 544 billion SEK |
Stockholm, 2021-02-09
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Novartis Pharma AG19.10.2025 16:30:00 CEST | Press release
PSMAddition data show Novartis Pluvicto™ delays progression to end-stage prostate cancer
Genmab A/S18.10.2025 12:00:34 CEST | Press release
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer
F. Hoffmann-La Roche Ltd18.10.2025 07:00:00 CEST | Press release
Roche’s phase III evERA data showed giredestrant significantly improved progression-free survival in people with ER-positive advanced breast cancer
StoneX Group Inc.18.10.2025 01:12:36 CEST | Press release
StoneX Expands Wealth Management Offering for Latin American Clients
F. Hoffmann-La Roche Ltd17.10.2025 22:20:00 CEST | Press release
Roche presents new phase III pivotal data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom